Harmony Biosciences Holdings, Inc. (HRMY)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research

Current Price

as of Mar 12, 2025

$33.60

P/E Ratio

13.36

Market Cap

$1.88B

Mar 20, 2024Apr 24, 2024May 29, 2024Jul 2, 2024Aug 2, 2024Sep 5, 2024Oct 8, 2024Nov 11, 2024Dec 17, 2024Jan 24, 2025Mar 12, 2025$20.00$30.00$40.00$50.00
  • HRMY
Description
Add to research

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

Metrics
Add to research

Overview

  • HQPlymouth Meeting, PA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerHRMY
  • Price$33.6-0.15%

Trading Information

  • Market cap$1.88B
  • Float75.82%
  • Average Daily Volume (1m)780,649
  • Average Daily Volume (3m)636,324
  • EPS$2.56

Company

  • Revenue$714.73M
  • Rev growth (1yr)22.80%
  • Net income$145.49M
  • Gross margin74.72%
  • EBITDA margin30.07%
  • EBITDA$214.94M
  • EV$1.76B
  • EV/Revenue2.46
  • P/E13.36
  • P/S2.72
  • P/B2.91
  • Debt/Equity35.37
Documents
Add to research